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Abstract
Sepsis is a systemic inflammatory response triggered by microbial infection
that can cause cardiovascular collapse, insufficient tissue perfusion and
multi-organ failure. The cation channel transient receptor potential vanilloid 4
(TRPV4) is expressed in vascular endothelium and causes vasodilatation, but
excessive TRPV4 activation leads to profound hypotension and circulatory
collapse - key features of sepsis pathogenesis. We hypothesised that loss of
TRPV4 signaling would protect against cardiovascular dysfunction in a mouse
model of sepsis (endotoxaemia).
Multi-parameter monitoring of conscious systemic haemodynamics (by
radiotelemetry probe), mesenteric microvascular blood flow (laser speckle
contrast imaging) and blood biochemistry (iSTAT blood gas analysis) was
carried out in wild type (WT) and TRPV4 knockout (KO) mice. Endotoxaemia
was induced by a single intravenous injection of lipopolysaccharide (LPS; 12.5
mg/kg) and systemic haemodynamics monitored for 24 h. Blood flow recording
was then conducted under terminal anaesthesia after which blood was
obtained for haematological/biochemical analysis. No significant differences
were observed in baseline haemodynamics or mesenteric blood flow. Naïve
TRPV4 KO mice were significantly acidotic relative to WT counterparts.
Following induction of sepsis, all mice became significantly hypotensive,
though there was no significant difference in the degree of hypotension
between TRPV4 WT and KO mice. TRPV4 KO mice exhibited a higher sepsis
severity score. While septic WT mice became significantly hypernatraemic
relative to the naïve state, this was not observed in septic KO mice. Mesenteric
blood flow was inhibited by topical application of the TRPV4 agonist
GSK1016790A in naïve WT mice, but enhanced 24 h following LPS injection.
Contrary to the initial hypothesis, loss of TRPV4 signaling (either through gene
deletion or pharmacological antagonism) did not attenuate sepsis-induced
cardiovascular dysfunction: in fact, pathology appeared to be modestly
exaggerated in mice lacking TRPV4. Local targeting of TRPV4 signalling may
be more beneficial than global inhibition in sepsis treatment.
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Introduction
Sepsis, the systemic inflammatory syndrome that can occur in 
response to infection, represents an enormous global healthcare 
burden; it can progress to septic shock, characterised by refractory 
hypotension and insufficient organ perfusion, with associated mor-
tality rates of up to 80% (Martin, 2012). However, treatment options 
for sepsis are currently limited, highlighting the need to refine pre-
clinical septic shock models to allow more effective identification 
of novel drug targets. There is now increasing evidence that several 
cation-permeable transient receptor potential (TRP) channels, most 
notably of the vanilloid (TRPV) subfamily, can influence physio-
logical systems compromised in sepsis, and may represent potential 
therapeutic targets.
TRPV4, originally identified as an osmosensor in the kidney (Liedtke 
et al., 2000; Strotmann et al., 2000; Wissenbach et al., 2000), is 
expressed in numerous tissues, including the heart and vasculature 
(Wissenbach et al., 2000). Its expression in both endothelial and 
smooth muscle cells is well-established, and its activation in vas-
cular tissue is associated with endothelium-dependent vasodilata-
tion, and both direct and indirect smooth muscle hyperpolarisation 
(Baylie & Brayden, 2011). In addition to extracellular hypotonic-
ity, it is gated by various physical and chemical stimuli, including 
shear stress, arachidonic acid metabolites (particularly epoxyeico-
satrienoic acids) and endocannabinoids (Nilius et al., 2004). These 
chemical factors may be increased under inflammatory conditions 
(Kiss et al., 2010; Theken et al., 2011; Varga et al., 1998). Fur-
thermore, previous studies have identified sensitisation of TRPV4 
without direct activation by other common inflammatory mediators 
(Alessandri-Haber et al., 2006). Recent reports have linked exces-
sive TRPV4 activation to lethal endothelial failure, oedema forma-
tion, hypotension and circulatory collapse (Sonkusare et al., 2012; 
Willette et al., 2008), suggesting it may play a key role in sepsis 
pathogenesis. Given that numerous endogenous agonists and sen-
sitisers of TRPV4 are upregulated in sepsis, we hypothesised that 
blockade of TRPV4 activity using a pharmacological antagonist 
HC-067047, or genetic deletion of the channel (in global knockout 
mice) would be protective in a murine model of sepsis, attenuat-
ing the cardiovascular collapse associated with the development of 
septic shock.
Methods
Materials
Lipopolysaccharide (LPS) from Salmonella typhimurium and 
the TRPV4 agonist GSK1016790A were purchased from Sigma-
Aldrich. The TRPV4 antagonist HC-067047 was purchased from 
Tocris Bioscience. All other materials were obtained from Sigma-
Aldrich, unless otherwise stated.
Animals
Male mice, either wild type (WT) or littermates lacking functional 
TRPV4 (KO), were bred in-house from heterozygous breeding 
pairs originally derived from a colony generated by Liedtke & 
Friedman (Liedtke & Friedman, 2003). Mice were maintained on a 
12-h light/dark cycle (7am–7pm, and 7pm–7am, respectively) and 
given access to food (normal chow) and water ad libitum. All ani-
mal experiments were conducted under a UK Home Office licence 
(PPL 70/7049), following local ethics committee approval and in 
accordance with the Home Office Animal (Scientific Procedures) 
Act, 1986. Experiments were designed and conducted in a blinded 
manner and in accord with the ARRIVE guidelines (Kilkenny, 
2010). All treatments were randomised. Mice were used between 
10 and 14 weeks of age (approx. 25–30g). Individual mice were 
considered to be independent experimental units. A power calcula-
tion on pilot laser perfusion imaging data (α = 0.05; β = 0.2; mini-
mum effect size = 20% alteration in blood flux value) indicated that 
6 mice in each experimental group would provide sufficient power.
Induction of endotoxaemia
LPS-induced endotoxaemia was used as a model for sepsis. Endo-
toxaemia was induced by intravenous injection of the bacterial 
endotoxin LPS (12.5 mg/kg). Injections of 100 µl (pre-warmed to 
37°C) were administered into the tail vein (using a 29 G needle and 
insulin syringe) under inhaled isoflurane anaesthesia (2% by air 
pump). A heating mat set to 37°C was used to dilate the tail vein 
for improved accessibility. Buprenorphine hydrochloride [15 µg/kg, 
intramuscular (i.m.)] was administered into the two hind-limbs to 
provide post-operative analgesia and 0.9% (w/v) saline (20 ml/kg) 
was administered subcutaneously to provide fluid resuscitation. 
Mice were placed in a recovery chamber at 27°C for up to 24 h 
and were monitored frequently. An arbitrary severity score of 1–5 
(based on mobility, facial expression, piloerection and aversion to 
touch) was employed to assess animal welfare. Any mouse reaching 
a score of 5 was immediately euthanised. All scoring was conducted 
by an experimenter blind to mouse genotype and treatment.
Multi-parameter monitoring
A multi-parameter approach, encompassing haemodynamic, micro-
circulatory and haematological assessment, was used to determine 
the impact of TRPV4 blockade on endotoxaemia pathophysiology, 
as described previously (Sand et al., 2015). A timeline summarising 
the sequence of experimental procedures is provided in Figure 1. 
Haemodynamic recording
PA-C10 telemetry probes (Data Sciences International; DSI, USA) 
were implanted into 10–12-week-old mice weighing 25–30g, under 
inhaled isoflurane anaesthesia using aseptic technique. Mice were 
placed in the supine position on a homeothermically-controlled 
heating mat (Harvard Instruments), and the thorax was shaved 
and disinfected with chlorhexidine. Buprenorphine hydrochloride 
(15 µg/kg, i.m.) was administered into the two hind-limbs to provide 
post-operative analgesia, and eyes were protected with Viscotears. 
A small thoracic incision was made and the carotid artery was iso-
lated by gentle blunt dissection. Telemeter catheters were advanced 
into the left carotid artery and secured with three silk sutures. The 
body of the telemetry probe was placed in a subcutaneous pocket 
in the flank of the animal, and the incision was closed using a 5.0 
Vicryl suture. Mice were then placed in a recovery cabinet at 27°C 
for 4 h, before being moved to a holding room, where they were 
allowed to recover for at least 7 days before the start of haemo-
dynamic monitoring. The viability of each haemodynamic trace 
was checked, and mice with significant dampening or loss of signal 
were excluded from analysis (two in this study). All implantation, 
monitoring and data analysis were conducted by an experimenter 
blind to mouse genotype and treatment, and assignment of telem-
etry probes was randomised.
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Following recovery, baseline haemodynamic parameters were 
recorded over a 48-h weekend period. Food and water intake was 
measured continuously, and mice were closely monitored for 
adverse signs. After baseline recordings, the TRPV4 antagonist HC-
067047 [10 mg/kg in 500 µl saline, intraperitoneal (i.p.)] or vehicle 
(10% dimethyl sulfoxide, DMSO, in 500 µl saline, i.p.) was admin-
istered in a blinded and randomised fashion to WT mice only. KO 
mice were left untreated. Baseline haemodynamic parameters were 
then recorded over a second 48-h weekend period. On the following 
Monday, TRPV4 WT mice were re-injected with either HC-067047 
or vehicle (the same as the first treatment), and endotoxaemia was 
induced by intravenous administration of LPS. Haemodynamic 
parameters were recorded for a further 24 h, and mice were then 
terminally anaesthetised for blood flow assessment.
PA-C10 telemetry probes allow continuous and remote monitoring 
of blood pressure, heart rate and locomotor activity in freely mov-
ing conscious animals. Data were acquired continuously at 500 Hz 
using standard acquisition software (DSI, USA). Baseline record-
ing was carried out over weekends in order to minimise disruption.
In situ monitoring of mesenteric blood flow
In light of evidence suggesting that microvascular circulation is 
more prognostic in sepsis than global haemodynamics (De Backer 
et al., 2002; Sakr et al., 2004), we analysed mesenteric blood flow 
in TRPV4 WT and KO mice, both at baseline and during endotox-
aemia. The mesenteric bed was chosen for assessment of microcir-
culatory function for its accessibility and its significant contribution 
to peripheral vascular resistance.
Mesenteric blood flow was measured in naïve and endotoxaemic 
mice under inhaled isoflurane anaesthesia (2% delivered by air 
pump), as described previously (Sand et al., 2015). Core tem-
perature was recorded and controlled by a rectal probe coupled 
to a homeothermic heating mat (Harvard Instruments); mice were 
maintained at the temperature at which they initially presented. The 
abdominal region was shaved, and a small midline incision was 
made. A portion of the small intestine was gently exteriorised onto 
a Parafilm-coated heating mat, and was pinned out through the gut 
wall to expose the mesenteric vasculature. The exposed vascular 
bed was kept moist with saline (0.5 ml, aerosolised) pre-warmed to 
37°C. An additional heating mat was placed over the anaesthetised 
animal.
Mesenteric blood flow was recorded using a moorFLPI full-field 
laser perfusion imaging system and review software (Moor Instru-
ments, Devon, UK) either in naïve animals, or at 6 or 24 h after the 
induction of endotoxaemia. The following acquisition modes and 
settings were used: high resolution capture (25 frames, 1 s/frame); 
exposure 20 ms; automatic gain; flux palette set at 0–5000; back-
ground threshold 60 flux units. Vessels within the field of view 
were designated as 1st, 2nd or 3rd order branches of the mesenteric 
tree, and regions of interest, in which flux over time was measured, 
were defined in each visible vessel. All assessment and analysis was 
performed by an experimenter blind to mouse genotype and treat-
ment. Baseline recordings were taken over 5 min, after which the 
mesenteric bed was gently sprayed (two pump compressions from 
a distance of approximately 10 cm) with selective TRPV4 agonist 
GSK1016790A (1 µM) dissolved in saline containing 1% DMSO, 
and pre-warmed to 37°C. Responses to GSK1016790A were meas-
ured over a further 5 min. Data were analysed in moorFLPI Review 
software (V 4.0; Moor Instruments, UK) and GraphPad Prism 
(V 5.0; GraphPad Software Inc, USA), and are expressed as mean 
area under the curve (AUC) over time ± SEM.
Analysis of blood biochemistry
Following blood flow recording, a venous blood sample was drawn 
from the inferior vena cava, and animals were killed by cervical 
dislocation. Blood biochemistry was assessed immediately from 
100 µl venous blood using a hand-held iSTAT® point-of-care 
analyser (Abbott Laboratories, IL, USA), with CG8+ cartridges 
(Abbott Laboratories).
Figure 1. Timeline of experimental procedures. Mice were implanted with telemetry probes on day 1, and were left to recover for 10 days. 
Basal haemodynamic data were then recorded over a 48-h weekend period (BL1). The following weekend, WT mice were injected with either 
vehicle (10% DMSO in saline) or TRPV4 antagonist HC-067047 (10 mg/kg, i.p.) and a second 48-h baseline recording (BL2) was taken for all 
mice. TRPV4 KO mice were left untreated. Injections in WT mice were performed in a randomised and blinded fashion. Following the second 
weekend baseline recording, WT mice received a second injection of either HC-067047 or vehicle (consistent with initial treatment) and LPS 
(12.5 mg/kg, i.v.) was administered to all mice. Haemodynamic data were recorded over 24-h of endotoxaemia progression. Mice were then 
terminally anaesthetised for blood flow recording and ex vivo analysis. A separate cohort of naïve mice were included in blood flow and 
ex vivo studies.
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Assessment of organ oedema
Oedema formation was measured by comparing wet and dry weights 
of lungs, hearts, upper liver lobes, right kidneys, 1 cm sections of 
small intestine and whole spleens. Tissues were excised immedi-
ately after blood flow recording and wet weights were recorded. 
Samples were then placed in an oven at 50°C until a constant dry 
weight was reached (approximately 3 days). The ratio of wet weight: 
dry weight was used as an indication of oedema formation.
Statistical analysis
Statistical analysis was conducted in GraphPad Prism. Mean data 
for ‘n’ number of animals were compared by 1-way ANOVA with 
Bonferroni post-hoc test, unless stated otherwise. The threshold for 
statistical significance was p < 0.05.
Results
TRPV4 WT and KO mice were singly-housed from the time of 
radiotelemeter implantation throughout the duration of the study. 
Food and water intake were monitored throughout. Recovery from 
telemetry surgery (measured as recovery in body weight, food and 
water intake and physical examination) was equivalent across all 
animals. All mice returned to their pre-surgery weight and food 
water intake within 7 days of implantation. Following recovery, 
TRPV4 KO mice were found to consume less water than WT 
counterparts, though this difference was not statistically significant 
(Figure 2a). Systemic administration of either HC-067047 or its 
vehicle to WT mice reduced water intake, though the magnitude 
of change was significantly greater in HC067047-treated animals 
(Figure 2b). Water intake was reduced in all animals over the 
24 h following the induction of endotoxaemia (Figure 2c). No dif-
ference in food intake was observed between different genotypes 
basally (Figure 2d). Systemic administration of either vehicle 
or HC-067047 reduced food intake, though to a similar degree 
across treatment groups (Figure 2e). Induction of sepsis with LPS 
[12.5 mg/kg, intravenous (i.v.)] markedly reduced food intake to a 
similar degree in all groups (Figure 2f).
Dataset 1. Raw Data for Figure 2
http://dx.doi.org/10.5256/F1000Research.6298.d45231
Water and food intake in TRPV4 WT and KO mice before and after 
induction of endotoxaemia. Basal water intake was measured in 
TRPV4 WT and KO mice over approximately 1 week (not including 
7-day recovery period from telemetry surgery). Change in water 
intake was measured over 24-h period following i.p. administration 
of either vehicle (10% DMSO) or HC-067047, as well as during 
the 24-h period following administration of LPS (12.5 mg/kg i.v.). 
Basal food intake in TRPV4 WT and KO mice was measured over 
approximately 1 week (not including 7-day recovery period from 
telemetry surgery). Change in food intake was measured over 
24-h period following i.p. administration of either vehicle (10% 
DMSO) or HC-067047, as well as during the 24-h period following 
administration of LPS (12.5 mg/kg i.v.) (Sand et al., 2015a).
Under basal conditions, all animals exhibited diurnal variation in 
blood pressure, heart rate and ambulatory activity (Figure 3), within 
the expected physiological range for mice (Curtis et al., 2007). 
No significant difference in basal haemodynamic parameters was 
observed between genotypes, although TRPV4 KO mice exhibited 
Figure 2. Water and food intake in TRPV4 WT and KO mice before and after induction of endotoxaemia. (a) Mean basal water intake 
in TRPV4 WT and KO mice over approximately 1 week (not including 7-day recovery period from telemetry surgery). (b) Change in water 
intake over 24-h period following i.p. administration of either vehicle (10% DMSO) or HC-067047. (c) Water intake over 24-h period following 
administration of LPS (12.5 mg/kg i.v.). (d) Mean basal food intake in TRPV4 WT and KO mice over approximately 1 week (not including 7-day 
recovery period from telemetry surgery). (e) Change in food intake over 24-h period following i.p. administration of either vehicle (10% DMSO) 
or HC-067047. (f) Food intake over 24-h period following administration of LPS (12.5 mg/kg i.v.). Data for individual animals are represented 
as individual symbols, with group mean denoted by horizontal line. *p<0.05, relative to vehicle-treated controls, 1-way ANOVA + Bonferroni 
post-hoc test, n = 5–12.
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a trend towards lower blood pressure (both daytime and night-
time) and lower daytime ambulatory activity than WT counterparts 
[average mean arterial pressure (MAP) over 24 h: KO = 93.71 ± 
2.83 mmHg vs. WT = 99.89 ± 1.87 mmHg, ns; mean daytime activ-
ity over 12 h: KO = 3.25 ± 0.43 counts/min vs. WT = 4.31 ± 0.33 
counts/min, ns (n = 5–10)] (Figure 3a,c,d,f).
Systemic administration of the TRPV4 antagonist HC-067047 
caused an increase in mean daytime blood pressure of approxi-
mately 5 mmHg, though this was reversed after 12 h, leading to 
small but consistent decrease in night-time pressure (Table 1). 
Systemic administration of vehicle (10% DMSO in saline) also 
caused an increase in blood pressure, though this was more tran-
sient (Table 1 & Figure 3). Neither administration of HC-067047 
nor of vehicle significantly altered any other haemodynamic param-
eters under basal conditions, though heart rate was transiently 
increased relative to time-matched pre-treatment values in both 
groups, and subsequently declined during night-time (Table 1). In 
both cases (daytime tachycardia and night-time bradycardia) the 
magnitude of the change was greater in HC-067047-treated mice 
than in vehicle-treated controls, though this was not statistically 
significant. Mice treated with HC-067047 did exhibit significantly 
greater daytime ambulatory activity, relative to time-matched 
pre-treatment values (Table 1); this change was not observed in 
vehicle-treated animals, and was no longer evident during night-
time hours.
Since TRPV4 KO mice were not treated with pharmacological 
stimuli, baseline parameters were simply re-recorded in the same 
mice. Values were relatively consistent across separate baseline 
recording periods (Table 1), confirming the robustness of the moni-
toring system.
Systemic administration of LPS caused a significant decline in blood 
pressure in all animals (Figure 3a,c,d & Table 1), that began to sta-
bilise after approximately 12 h. No significant difference between 
genotypes was observed, though both TRPV4 KOs and antagonist-
treated mice exhibited a trend towards more severe hypotension, 
particularly in systolic pressure (Figure 3a,c and Table 1). Pulse 
pressure was compromised in TRPV4 KO and HC-067047-treated 
mice, relative to vehicle-treated controls (Figure 3e and Table 1).
An immediate increase in heart rate was observed in both HC-
067047- and vehicle-treated WT animals following the induction 
of endotoxaemia, and this tachycardia was sustained during day-
light hours. TRPV4 KO mice exhibited a transient increase in heart 
rate immediately after LPS administration, but became bradycardic 
thereafter, indicating failure of the baroreceptor reflex (Figure 3b and 
Table 1). All mice exhibited marked bradycardia during night-time 
hours, relative to time-matched pre-LPS values, though the mag-
nitude of the decrease was greatest in TRPV4 KO mice (Table 1). 
Ambulatory activity was almost entirely abolished in all mice fol-
lowing the induction of endotoxaemia (Figure 3f).
Figure 3. Haemodynamic monitoring in TRPV4 WT and KO mice under basal and endotoxaemic conditions. (a) Mean arterial 
pressure, (b) heart rate, (c) systolic pressure, (d) diastolic pressure, (e) pulse pressure and (f) locomotor activity at baseline (BL1), 
following systemic treatment (WT mice only) with HC-067047 (HC) or vehicle (10% DMSO) (BL2) and after induction of endotoxaemia (at 
time 48 h: LPS, 12.5 mg/kg, i.v.). Boxed regions denote periods of darkness. Data were acquired by radiotelemetry in conscious, ambulatory 
male C57BL/6 mice, and are presented as mean ± SEM, n = 4–6.
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Table 1. Statistical comparison of haemodynamic parameters in TRPV4 WT and KO mice under basal and endotoxaemic conditions. 
Data are presented as mean difference (95% CI), and are divided into daytime and night-time phases. BL1 represents mean baseline values 
in untreated mice over 48-h weekend recording. BL2 represents mean baseline values following i.p. treatment (WT mice only) with vehicle 
(10% DMSO) or HC-067047; BL2 in KO mice represents a separate untreated 48-h baseline recording. LPS represents mean values following 
systemic treatment with LPS (12.5 mg/kg, i.v.) over 24-h recording period. *p<0.05, **p<0.01, ***p<0.001, 1-way ANOVA + Bonferroni post-
hoc test.
Mean arterial pressure, mean diff (95% CI), mm Hg 
Day Night 
Comparison WT + Vehicle  (n = 4)
WT + HC-067047  
(n = 6)
TRPV4 KO  
(n = 5)
WT + Vehicle  
(n = 4)
WT + HC-067047  
(n = 6)
TRPV4 KO  
(n = 5)
BL1 – BL2 +4.835 (-10.99 to +20.66)
+5.297 
(-7.62 to +18.21)
-0.406 
(-14.56 to +13.74)
-1.532 
(-13.82 to +10.75)
-4.956 
(-14.99 to +5.08)
-2.327 
(-13.32 to +8.66)
BL1 – LPS -2.838 (-18.66 to +12.98)
-2.124 
(-15.04 to +10.79)
-4.326 
(-18.48 to +9.825)
-14.480** 
(-29.77 to +2.19)
-19.020*** 
(-29.05 to -8.99)
-15.410*** 
(-26.4 to -4.418)
BL2 – LPS -7.674 (-23.49 to +8.147)
-7.421 
(-20.34 to +5.50)
-3.920 
(-18.07 to +10.23)
-12.95* 
(-25.23 to +0.66)
-14.060 
(-24.09 to -4.03)
-13.080** 
(-24.07 to -2.09)
Systolic pressure, mean diff (95% CI), mm Hg 
Day Night 
Comparison WT + Vehicle  (n = 4)
WT + HC-067047  
(n = 6)
TRPV4 KO  
(n = 5)
WT + Vehicle  
(n = 4)
WT + HC-067047  
(n = 6)
TRPV4 KO  
(n = 5)
BL1 – BL2 +4.523 (-14.82 to +23.87)
+5.443 
(-10.35 to +21.24)
-1.898 
(-19.20 to +15.41)
-0.935 
(-19.33 to +17.46)
-3.393 
(-18.41 to +11.62)
-2.923 
(-19.37 to +13.53)
BL1 – LPS -7.558 (-26.90 to +11.79)
-6.681 
(-22.48 to +9.12)
-9.699 
(-27.00 to +7.61)
-14.64 
(-33.03 to +3.75)
-22.590*** 
(-37.61 to -7.58)
-19.870** 
(-36.32 to -3.42)
BL2 – LPS -12.08 (-31.43 to +7.27)
-12.12 
(-27.92 to +3.67)
-7.801 
(-25.10 to +9.50)
-13.70 
(-32.10 to +4.69)
-19.20** 
(-34.22 to -4.19)
-16.94* 
(-33.39 to -0.49)
Diastolic pressure, mean diff (95% CI), mm Hg 
Day Night 
Comparison WT + Vehicle  (n = 4)
WT + HC-067047  
(n = 6)
TRPV4 KO  
(n = 5)
WT + Vehicle  
(n = 4)
WT + HC-067047  
(n = 6)
TRPV4 KO  
(n = 5)
BL1 – BL2 +4.175 (-12.49 to +20.84)
+3.614 
(-10.00 to +17.22)
-0.3836 
(-15.29 to +14.53)
-1.603 
(-13.95 to +10.75)
-6.103 
(-16.19 to +3.98)
-0.263 
(-11.31 to +10.78)
BL1 – LPS -0.366 (-17.04 to +16.30)
+1.581 
(-12.03 to +15.19)
+2.953 
(-11.96 to +17.86)
-13.410* 
(-25.76 to -1.06)
-15.940*** 
(-26.03 to -5.86)
-9.740 
(-20.79 to +1.307)
BL2 – LPS -4.541 (-21.21 to +12.13)
-2.033 
(-15.64 to +11.58)
+3.337 
(-11.57 to +18.25)
-11.810 
(-24.16 to +0.54)
-9.841 
(-19.93 to +0.24)
-9.476 
(-20.52 to +1.57)
Heart rate, mean diff (95% CI), bpm 
Day Night 
Comparison WT + Vehicle  (n = 4)
WT + HC-067047  
(n = 6)
TRPV4 KO  
(n = 5)
WT + Vehicle  
(n = 4)
WT + HC-067047  
(n = 6)
TRPV4 KO  
(n = 5)
BL1 – BL2 +18.45 (-80.45 to +117.40)
+22.51 
(-58.25 to +103.30)
-0.96 
(-89.43 to +87.50)
-19.20 
(-126.00 to +87.55)
-34.53 
(-121.70 to +52.63)
-10.50 
(-106 to +84.98)
BL1 – LPS +23.19 (-75.75 to +122.10)
+56.30 
(-24.46 to +137.10)
-2.04 
(-90.50 to +86.42)
-57.22 
(-164.00 to +49.54)
-42.61 
(-129.80 to +44.55)
-86.79 
(-182.30 to +8.69)
BL2 – LPS +4.74 (-94.17 to 103.60)
+33.79 
(-46.97 to +114.50)
-1.08 
(-89.54 to +87.39)
-38.01 
(-144.80 to +68.74)
-8.076 
(-95.24 to +79.09)
-76.29 
(-171.80 to +19.20)
Pulse pressure, mean diff (95% CI), mm Hg 
Day Night 
Comparison WT + Vehicle  (n = 4)
WT + HC-067047  
(n = 6)
TRPV4 KO  
(n = 5)
WT + Vehicle  
(n = 4)
WT + HC-067047  
(n = 6)
TRPV4 KO  
(n = 5)
BL1 – BL2 +1.049 (-13.99 to +16.08)
+1.941 
(-10.33 to +14.22)
-0.475 
(-13.92 to +12.97)
+1.003 
(-17.85 to +19.86)
+1.149 
(-14.24 to +16.54)
-2.314 
(-19.18 to +14.55)
BL1 – LPS -6.405 (-21.44 to +8.63)
-9.437 
(-21.71 to +2.84)
-11.62 
(-25.06 to +1.83)
-0.939 
(-19.79 to +17.91)
-6.659 
(-22.05 to +8.74)
-9.965 
(-26.83 to +6.90)
BL2 – LPS -7.454 (-22.49 to +7.58)
-11.38 
(-23.65 to +0.90)
-11.14 
(-24.59 to +2.31)
-1.943 
(-20.80 to +16.91)
-7.808 
(-23.20 to +7.59)
-7.651 
(-24.51 to +9.21)
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Activity, mean diff (95% CI), counts/min 
Day Night 
Comparison WT + Vehicle  (n = 4)
WT + HC-067047  
(n = 6)
TRPV4 KO  
(n = 5)
WT + Vehicle  
(n = 4)
WT + HC-067047  
(n = 6)
TRPV4 KO  
(n = 5)
BL1 – BL2 +1.548 (-1.97 to +5.07)
+3.260* 
(+0.39 to +6.14)
+0.880 
(-2.27 to +4.03)
-0.114 
(-4.20 to -397)
-0.360 
(-3.69 to +2.97)
-2.169 
(-3.30 to +3.69)
BL1 – LPS -3.764 (-7.29 to +0.24)
-2.762 
(-5.64 to +0.11)
-1.568 
(-4.72 to +1.58)
-8.932*** 
(-13.02 to -4.85)
-5.788*** 
(-9.12 to -2.45)
-7.105*** 
(-10.76 to -3.45)
BL2 – LPS -5.311*** (-8.83 to +1.79)
-6.023*** 
(-8.90 to -3.15)
-2.448 
(-5.60 to +0.70)
-8.818*** 
(-12.90 to -4.74)
-5.428*** 
(-8.76 to -2.09) 
-4.936** 
(-8.59 to -1.28)
Dataset 2. Raw Data for Figure 3
http://dx.doi.org/10.5256/F1000Research.6298.d45232
Haemodynamic monitoring in TRPV4 WT and KO mice under 
basal and endotoxaemic conditions. Values were taken following 
systemic treatment (WT mice only) with HC-067047 (HC) or vehicle 
(10% DMSO) (BL2) and after induction of endotoxaemia (at time 
48 h: LPS, 12.5 mg/kg, i.v.). Boxed regions denote periods of 
darkness. Data were acquired by radiotelemetry in conscious, 
ambulatory male C57BL/6 mice (Sand et al., 2015b).
All mice telemetered for haemodynamic recording were subjected 
to mesenteric blood flow analysis. A group of naïve animals were 
included for comparison, and additional vehicle- and HC-067047-
treated WT mice were used to increase statistical power.
Mesenteric blood flow was significantly reduced in all groups 24 h 
after the induction of endotoxaemia (Figure 4a–c). No significant 
differences were observed between genotypes or treatment groups, 
though endotoxaemic mice pre-treated with HC-067047 exhibited a 
trend towards improved flow. In order to determine whether blockade 
of TRPV4 may play a role earlier in pathogenesis, mesenteric flow 
was recorded in a separate cohort of WT mice treated for 6 h with 
HC-067047 and LPS. At this time-point, blood flow in HC-067047-
treated mice was decreased relative to vehicle-treated controls, 
though these changes were not statistically significant (Figure 4e–f).
Figure 4. Mesenteric blood flow in healthy and endotoxaemic TRPV4 WT and KO mice. (a–c) Mesenteric blood flow in TRPV4 KO mice 
and WT mice treated i.p. with vehicle (10% DMSO) or HC-067047 (HC) for 24 h, either under naïve or endotoxaemic (LPS 12.5 mg/kg, i.v., 
24 h) conditions. Data are expressed as total area under the curve (AUC; ×103 flux units.time) over 5-min baseline recording in 1st, 2nd and 3rd 
order vessels, respectively. **p<0.01, ***p<0.001, relative to naïve counterparts, 1-way ANOVA + Bonferroni post-hoc test. (d–f) Mesenteric 
blood flow in WT mice treated i.p. with vehicle (10% DMSO) or HC-067047, either under naïve (24-h treatment) or endotoxaemic conditions 
(6 h or 24 h; drugs administered simultaneously with LPS) in 1st, 2nd and 3rd order vessels, respectively. AUC for each animal is represented 
as an individual symbol, with horizontal line denoting group mean, n = 6–9.
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Dataset 3. Raw Data for Figure 4
http://dx.doi.org/10.5256/F1000Research.6298.d45233
Mesenteric blood flow in healthy and endotoxaemic TRPV4 WT 
and KO mice. TRPV4 KO mice and WT mice were treated i.p. with 
vehicle (10% DMSO) or HC-067047 (HC) for 24 h, either under 
naïve or endotoxaemic (LPS 12.5 mg/kg, i.v., 24 h) conditions 
(Sand et al., 2015c).
Antagonism or gene ablation of TRPV4 had only minor effects 
on clinical phenotype, though in opposing directions. In line with 
marginally improved mesenteric perfusion, antagonist-treated mice 
exhibited a lower sepsis severity score after 24 h treatment with 
LPS, relative to vehicle-treated controls. On the other hand, the 
severity score in TRPV4 KO mice was significantly greater than in 
antagonist-treated counterparts (Figure 5a). The percentage weight 
loss over 24 h of endotoxaemia was roughly equivalent between 
groups, but was lower in antagonist-treated and TRPV4 KO mice, 
than in vehicle-treated controls (Figure 5b). Core temperature 
decreased significantly in all LPS-treated mice, though remained 
stable in all animals throughout the recording period (Figure 5c). 
Although no statistically significant differences in core tempera-
ture were observed between groups, there were trends towards 
attenuated hypothermia in HC-067047-treated mice, and exagger-
ated hypothermia in TRPV4 KO mice, relative to vehicle-treated 
counterparts.
Dataset 4. Raw Data for Figure 5
http://dx.doi.org/10.5256/F1000Research.6298.d45234
Clinical parameters in TRPV4 WT and KO mice. An arbitrary 
severity score was assigned in a blinded fashion after 24-h 
treatment with LPS (12.5 mg/kg, i.v.) based on voluntary mobility, 
gait, aversion to touch, facial expression and piloerection. 
Percentage weight-loss after endotoxaemic period and core 
temperature were also measured. WT mice were treated i.p. 
with vehicle (10% DMSO) or HC-067047 (HC) at the time 
of LPS administration. TRPV4 KO mice did not receive any 
pharmacological treatment (Sand et al., 2015d).
Figure 5. Clinical parameters in TRPV4 WT and KO mice. (a) Arbitrary severity score assigned in a blinded fashion after 24-h treatment with 
LPS (12.5 mg/kg, i.v.) based on voluntary mobility, gait, aversion to touch, facial expression and piloerection. WT mice were treated i.p. with 
vehicle (10% DMSO) or HC-067047 (HC) at the time of LPS administration. TRPV4 KO mice did not receive any pharmacological treatment. 
(b) Percentage weight loss over 24-h endotoxaemic period. Values for each animal are presented as individual symbols, with horizontal line 
denoting group mean. #p<0.05, relative to HC-treated animals, 1-way ANOVA + Bonferroni post-hoc test (n = 8–9). (c) Core temperature 
measured by rectal probe throughout blood flow recording period. Data are presented as mean ± SEM (n = 8–9).
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Pharmacological TRPV4 antagonism and gene ablation also appeared 
to have divergent effects on blood biochemistry (Table 2). Although 
the concentration of urea was elevated in all groups 24 h post-
LPS, the increase in TRPV4 KO mice was greatest, whereas that 
in antagonist-treated mice did not reach statistical significance. 
Blood pH was also lowest in LPS-treated TRPV4 KO mice, 
whereas acidosis was attenuated in antagonist-treated mice, rela-
tive to vehicle-treated controls. PCO2 was increased by LPS treat-
ment, and bicarbonate decreased, indicative of respiratory and 
metabolic acidosis, respectively, though no significant differences 
were observed across treatment groups. All mice became signifi-
cantly hypoglycaemic following the induction of endotoxaemia. 
While both vehicle- and antagonist-treated animals became sig-
nificantly hypernatraemic and hyperchloraemic over the course 
of endotoxaemia, consistent with dehydration and loss of bicar-
bonate respectively, no change in plasma Na+ or Cl- levels was 
observed in TRPV4 KO mice. Correspondingly, bicarbonate levels 
decreased in both vehicle- and antagonist-treated mice, but not in 
TRPV4 KO mice. Both haemoglobin and haematocrit decreased 
slightly with endotoxaemia, though to an equivalent extent across 
groups.
Interestingly, naïve TRPV4 KO mice also exhibited trends towards 
pathological blood biochemistry. Blood pH was significantly 
decreased in these mice, and they also showed a trend to elevated 
blood urea concentration, relative to vehicle-treated WT controls. 
Basal haemoglobin and haematocrit levels were also decreased in 
naïve TRPV4 KO mice, relative to WT controls, indicative of basal 
anaemia (Table 2).
Dataset 5. Raw Data for Table 2
http://dx.doi.org/10.5256/F1000Research.6298.d45237
Blood biochemistry in healthy and endotoxaemic TRPV4 WT 
and KO mice. Blood gas and biochemistry were measured from 
venous blood samples by iSTAT point-of-care analyser in either 
TRPV4 KO mice, or WT mice treated i.p. with vehicle (10% DMSO) 
or HC-067047 (HC) for 24 h, either under naïve or endotoxaemic 
(LPS 12.5 mg/kg, i.v., 24 h) conditions. Abbreviations: PCO2, 
partial pressure of CO2; TCO2, total carbon dioxide; PCV, packed 
cell volume; HC, HC-067047; KO, TRPV4 knockout; LPS, 
lipopolysaccharide (Sand et al., 2015e).
The effect of pharmacological TRPV4 antagonism was also assessed 
at an earlier time-point in pathogenesis. In contrast with the 24 h 
time-point, no significant difference in severity score, percentage 
weight loss, or core temperature was observed between vehicle- and 
antagonist-treated mice at 6 h post-LPS (data not shown). Blood 
biochemistry was similarly equivalent between treatment groups at 
the 6 h time-point (Table 3).
Table 2. Blood biochemistry in healthy and endotoxaemic TRPV4 WT and KO mice. Blood gas and biochemistry were measured 
from venous blood samples by iSTAT point-of-care analyser in either TRPV4 KO mice, or WT mice treated i.p. with vehicle (10% DMSO) 
or HC-067047 (HC) for 24 h, either under naïve or endotoxaemic (LPS 12.5 mg/kg, i.v., 24 h) conditions. Data are presented as mean ± 
SEM. *p<0.05, **p<0.01, ***p<0.001, relative to naïve controls; #p<0.05, relative to vehicle-treated controls, 1-way ANOVA + Bonferroni 
post-hoc test (n = 6–9).
Vehicle Naïve HC Naïve KO Naïve Vehicle LPS HC LPS KO LPS
Urea (mmol/L) 5.100 ± 0.51 4.938 ± 0.44 5.417 ± 0.39 22.45 ± 5.55* 18.53 ± 3.81 30.30 ± 4.85***
pH 7.314 ± 0.01 7.291 ± 0.01 7.189 ± 0.03# 7.095 ± 0.03*** 7.156 ± 0.02** 7.090 ± 0.04
Base excess (mmol/L) -12.38 ± 0.80 -11.38 ± 1.03 -14.83 ± 0.79 -17.75 ± 1.05 -16.11 ± 1.23 -16.78 ± 2.05
HCO3- (mmol/L) 13.73 ± 0.88 15.41 ± 1.09 13.55 ± 0.94 11.90 ± 0.73 12.88 ± 1.26 13.14 ± 1.74
PCO2 (mmHg) 27.25 ± 2.18 32.06 ± 2.40 36.65 ± 5.20 39.08 ± 3.15 36.90 ± 4.02 42.11 ± 4.99
TCO2 (mmol/L) 14.63 ± 0.92 16.50 ± 1.15 14.67 ± 1.02 13.13 ± 0.74 14.00 ± 1.36 14.33 ± 1.85
Glucose (mmol/L) 11.70 ± 1.03 12.36 ± 0.90 10.77 ± 1.10 1.08 ± 0.04*** 1.34 ± 0.12*** 1.76 ± 0.50***
Na+ (mmol/L) 150.3 ± 1.7 147.9 ± 1.0 150.2 ± 0.9 155.9 ± 0.9* 154.0 ± 1.1** 150.6 ± 1.0#
K+ (mmol/L) 4.088 ± 0.15 4.250 ± 0.19 4.150 ± 0.24 3.950 ± 0.30 3.589 ± 0.32 3.625 ± 0.23
Cl- (mmol/L) 121.8 ± 1.3 119.5 ± 0.8 124.0 ± 0.6 130.0 ± 1.6* 128.6 ± 1.0*** 124.3 ± 1.6#
Anion gap (mmol/L) 18.50 ± 0.53 17.25 ± 0.94 16.67 ± 0.92 18.50 ± 0.87 16.11 ± 1.11 16.25 ± 1.03
Haemoglobin (g/dl) 10.41 ± 0.54 10.93 ± 0.59 8.60 ± 0.25 9.43 ± 0.71 8.96 ± 7.33 9.53 ± 0.59
Haematocrit (%PCV) 30.63 ± 1.60 32.13 ± 1.74 25.25 ± 0.75 29.57 ± 1.17 27.88 ± 1.36 28.00 ± 1.72
Abbreviations: PCO2, partial pressure of CO2; TCO2, total carbon dioxide; PCV, packed cell volume; HC, HC-067047; KO, TRPV4 knockout; LPS, 
lipopolysaccharide
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Table 3. Blood biochemistry in healthy and endotoxaemic WT mice treated with TRPV4 antagonist or vehicle. Blood gas 
and biochemistry were measured from venous blood samples by iSTAT point-of-care analyser in WT mice treated i.p. with vehicle 
(10% DMSO) or HC-067047 (HC), either under naïve (24-h treatment) or endotoxaemic (LPS 12.5 mg/kg, i.v., 6 h or 24 h) conditions. 
Data are presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, relative to naïve controls, 1-way ANOVA + Bonferroni post-hoc 
test (n = 8–9).
Vehicle Naïve HC Naïve Vehicle LPS 6 h HC LPS 6 h Vehicle LPS 24 h HC LPS 24 h
Urea (mmol/L) 5.100 ± 0.51 4.938 ± 0.44 7.888 ± 0.51 7.838 ± 0.76 22.45 ± 5.55* 18.53 ± 3.81
pH 7.314 ± 0.01 7.291 ± 0.01 7.073 ± 0.03*** 7.090 ± 0.02*** 7.095 ± 0.03*** 7.156 ± 0.02**
Base excess (mmol/L) -12.38 ± 0.80 -11.38 ± 1.03 -19.00 ± 1.18* -18.63 ± 1.16** -17.75 ± 1.05 -16.11 ± 1.23
HCO3- (mmol/L) 13.73 ± 0.88 15.41 ± 1.09 11.09 ± 0.89 11.30 ± 1.13 11.90 ± 0.73 12.88 ± 1.26
PCO2 (mmHg) 27.25 ± 2.18 32.06 ± 2.40 38.25 ± 3.28 37.46 ± 4.41 39.08 ± 3.15 36.90 ± 4.02
TCO2 (mmol/L) 14.63 ± 0.92 16.50 ± 1.15 12.13 ± 0.97 12.38 ± 1.22 13.13 ± 0.74 14.00 ± 1.36
Glucose (mmol/L) 11.70 ± 1.03 12.36 ± 0.90 2.063 ± 0.52*** 1.838 ± 0.42*** 1.08 ± 0.04*** 1.34 ± 0.12***
Na+ (mmol/L) 150.3 ± 1.7 147.9 ± 1.0 156.8 ± 0.4** 156.6 ± 0.5*** 155.9 ± 0.9* 154.0 ± 1.1**
K+ (mmol/L) 4.088 ± 0.15 4.250 ± 0.19 3.788 ± 0.20 3.788 ± 0.33 3.950 ± 0.30 3.589 ± 0.32
Cl- (mmol/L) 121.8 ± 1.3 119.5 ± 0.8 131.3 ± 1.0*** 131.4 ± 0.9*** 130.0 ± 1.6* 128.6 ± 1.0***
Anion gap (mmol/L) 18.50 ± 0.53 17.25 ± 0.94 18.13 ± 1.11 17.50 ± 0.50 18.50 ± 0.87 16.11 ± 1.11
Haemoglobin (g/dl) 10.41 ± 0.54 10.93 ± 0.59 9.44 ± 0.64 9.23 ± 0.85 9.43 ± 0.71 8.96 ± 7.33 
Haematocrit (%PCV) 30.63 ± 1.60 32.13 ± 1.74 27.75 ± 1.92 29.14 ± 1.71 29.57 ± 1.17 27.88 ± 1.36
Abbreviations: PCO2, partial pressure of CO2; TCO2, total carbon dioxide; PCV, packed cell volume; HC, HC-067047; KO, TRPV4 knockout; LPS, 
lipopolysaccharide
Dataset 6. Raw Data for Table 3
http://dx.doi.org/10.5256/F1000Research.6298.d45238
Blood biochemistry in healthy and endotoxaemic WT mice treated 
with TRPV4 antagonist or vehicle. Blood gas and biochemistry 
were measured from venous blood samples by iSTAT point-of-care 
analyser in WT mice treated i.p. with vehicle (10% DMSO) or HC-
067047 (HC), either under naïve (24-h treatment) or endotoxaemic 
(LPS 12.5 mg/kg, i.v., 6 h or 24 h) conditions (Sand et al., 2015f).
Oedema formation was measured by comparing wet and dry weights 
of various tissues. Surprisingly, treatment with LPS for 24 h did not 
cause any appreciable oedema formation in WT mice. Endotoxae-
mic TRPV4 KO mice exhibited marginally elevated oedema for-
mation in the liver and spleen, and significantly increased oedema 
in the kidney. No difference was observed between vehicle and 
antagonist-treated mice (Figure 6).
Dataset 7. Raw Data for Figure 6
http://dx.doi.org/10.5256/F1000Research.6298.d45235
Oedema formation in TRPV4 WT and KO mice was measured 
by comparing wet and dry weights of various organs. WT mice 
treated i.p. with vehicle (10% DMSO) or HC-067047 (HC) for 24 h, 
either under naïve or endotoxaemic (LPS 12.5 mg/kg, i.v., 24 h) 
conditions (Sand et al., 2015g).
The effect of TRPV4 antagonism on oedema formation was also 
assessed at an earlier time-point in pathogenesis. In contrast with 
the 24-h time-point, significant liver oedema was observed in both 
vehicle- and HC-067047-treated mice after 6 h, though this had 
returned to baseline levels by 24 h post-LPS (Figure 7). No sig-
nificant difference in oedema formation was observed in any other 
tissues, however. No changes in the ratio of heart weight to body 
weight were observed following the induction of endotoxaemia in 
any of the animal groups.
Dataset 8. Raw Data for Figure 7
http://dx.doi.org/10.5256/F1000Research.6298.d45236
Oedema formation in WT mice treated with TRPV4 antagonist or 
vehicle. Oedema formation was measured by comparing wet and 
dry weights of organs. WT mice were treated i.p. with vehicle (10% 
DMSO) or HC-067047 (HC) at the time of LPS (12.5 mg/kg, i.v., 6 or 
24 h) (Sand et al., 2015h).
In order to assess changes in TRPV4 activity in vivo after the 
induction of endotoxaemia, 1 µM GSK1016790A and vehicle 
(2% DMSO in pre-warmed saline) were sequentially applied to 
the exposed mesenteric bed by aerosolised spray. No significant 
responses to GSK1016790A were observed in the mesenteric 
beds of naive mice: both vehicle and GSK1016790A caused a 
non-significant decrease in blood flow, likely to reflect evapora-
tive cooling (Figure 8a–c and Table 4). In LPS-treated mice, on 
the other hand, GSK1016790A caused an increase in blood flow 
(Figure 8d–f) that was significant in 2nd and 3rd order mesenteric 
vessels (Table 4).
Discussion
Based on observations that excessive TRPV4 activation can cause 
profound hypotension, endothelial failure and circulatory collapse 
(Willette et al., 2008), we hypothesised that enhanced TRPV4 
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Figure 6. Oedema formation in TRPV4 WT and KO mice. Oedema formation was measured by comparing wet and dry weights of 
(a) lungs, (b) hearts, (c) upper liver lobes, (d) right kidneys, (e) 1-cm sections of small intestine and (f) whole spleens. WT mice were treated 
i.p. with vehicle (10% DMSO) or HC-067047 (HC) for 24 h, either under naïve or endotoxaemic (LPS 12.5 mg/kg, i.v., 24 h) conditions. Values 
for each animal are presented as individual symbols, with horizontal line denoting group mean. ***p<0.001, relative to naïve controls, 1-way 
ANOVA + Bonferroni post-hoc test (n = 6–9).
Figure 7. Oedema formation in WT mice treated with TRPV4 antagonist or vehicle. Oedema formation was measured by comparing wet 
and dry weights of (a) lungs, (b) upper liver lobes, (c) hearts, (d) right kidneys, (e) 1-cm sections of small intestine and (f) whole spleens. WT 
mice were treated i.p. with vehicle (10% DMSO) or HC-067047 (HC) at the time of LPS (12.5 mg/kg, i.v., 6 or 24 h). Values for each animal are 
presented as individual symbols, with horizontal line denoting group mean. **p<0.01, ***p<0.001, relative to naïve controls, 1-way ANOVA + 
Bonferroni post-hoc test (n = 6–9).
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Table 4. Change in mesenteric blood flow following topical TRPV4 activation in naïve and septic mice. Baselines (BL), and 
responses to aerosolised vehicle (Veh; 10% DMSO in pre-warmed saline) and GSK1016790A (GSK; 1 µM) were recorded over 
sequential 5-min periods. Data are presented as mean percentage change in area under the curve over 5-min recording period. 
*p<0.05, **p<0.01, relative to vehicle response in the same mouse, paired 2-tailed Student’s T-test; #p<0.05 relative to corresponding 
response in naïve controls, 1-way ANOVA + Bonferroni post-hoc test (n = 5).
Naive LPS 24 h
1st order 2nd order 3rd order 1st order 2nd order 3rd order 
BL−Veh -7.33 ± 3.10% -8.39 ± 1.73% -1.10 ± 0.32% -3.00 ± 2.77% -1.18 ± 1.51% -2.22 ± 3.87%
Veh−GSK -7.61 ± 1.30% -8.46 ± 3.27% -3.42 ± 2.05% +12.11 ± 6.19% +14.71 ± 6.70%*,# +11.73 ± 8.72%**
Figure 8. Vasoactive responses to GSK1016790A and vehicle in healthy and endotoxaemic WT mice. Baseline mesenteric blood flow 
was recorded for 5 min in naïve (a–c) and endotoxaemic (d–f) mice, 24 h after injections of LPS. Vehicle (V; 2% DMSO in saline) was then 
administered as an aerosolised spray, followed by administration of GSK1016790A (G; 1 µM) 5 min later. Blood flow was recorded in (a & d) 
1st order, (b & e) 2nd order and (c & f) 3rd order mesenteric vessels. Data are presented as mean ± SEM. *p<0.05, area under the curve relative 
to baseline, 1-way ANOVA + Bonferroni post-hoc test (n = 5).
activity may contribute to haemodynamic and vascular dysfunc-
tion during sepsis. Numerous endogenous agonists and regulators 
of TRPV4, including anandamide (Varga et al., 1998), arachidonic 
acid and its metabolites (Bruegel et al., 2012), protein kinase A 
(Yang et al., 1997), shear stress and temperature have been shown to 
be upregulated or altered in sepsis. It is conceivable therefore, that 
inflammation-induced upregulation of endogenous factors could 
contribute to sepsis-associated circulatory failure via excessive 
TRPV4 activation. By extension, blockade of TRPV4 activity may 
be expected to attenuate the circulatory dysfunction that underlies 
sepsis pathogenesis. To test this hypothesis we used both TRPV4 
KO mice and the selective TRPV4 antagonist, HC-067047.
Consistent with previous reports (Nishijima et al., 2014; Zhang 
et al., 2009), TRPV4 KO mice exhibited lower basal arterial pres-
sure than WT counterparts during both daytime and night-time peri-
ods. This is surprising given that TRPV4 has been implicated in both 
nitric oxide- (NO) and endothelium-derived hyperpolarising factor 
(EDHF)-mediated vasodilatory responses to physical and chemical 
stimuli in both conduit and resistance arteries (Adapala et al., 2011; 
Hartmannsgruber et al., 2007; Köhler et al., 2006; Loot et al., 2008; 
Ma et al., 2013; Mendoza et al., 2010; Rath et al., 2012; Sonkusare 
et al., 2012; Zhang et al., 2009). A possible explanation is that 
loss of TRPV4 leads to compensatory upregulation of alternative 
vasodilatory pathways during development. Although studies of iso-
lated vessels from TRPV4 KO mice have shown impaired vasodila-
tation in response to a range of physiological stimuli (Earley et al., 
2009; Zhang et al., 2009), the effects of isolation and ex vivo culture 
may have altered the mechanisms regulating vascular tone. Alter-
natively, it is possible that loss of TRPV4 expression in vascular 
smooth muscle may represent loss of a vasoconstrictor mechanism. 
While numerous studies have suggested that TRPV4 in vascular 
smooth muscle couples with hyperpolarising K+ channels to induce 
vasodilatation (Earley et al., 2005; Earley et al., 2009), activation 
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of TRPV4 simultaneously across multiple cells (as opposed to very 
localised activation) may trigger Ca2+-dependent vasoconstriction to 
maintain a basal level of vascular tone. Indeed, TRPV4-mediated 
vasoconstriction has previously been demonstrated in the lung, 
where TRPV4 gene ablation suppresses the development of chronic 
hypoxic pulmonary hypertension (Xia et al., 2013).
Given that TRPV4 exhibits tonic activity both in heterologous 
expression systems (Strotmann et al., 2000) and in primary endothe-
lial cells (Sonkusare et al., 2012), its blockade may be expected to 
cause acute hypertension. While systemic administration of HC-
067047 did induce a transient increase in blood pressure under basal 
conditions, a similar effect was observed in vehicle-treated animals, 
suggesting that the transient hypertension may have been a stress 
response to manual handling. In accordance with these data, previ-
ous studies have shown that administration of a different TRPV4 
antagonist – GSK 2193874 – does not significantly alter blood pres-
sure after either acute intravenous administration or repeated oral 
gavage (Thorneloe et al., 2012).
The lack of any dramatic effect on blood pressure is consistent 
with a previous ex vivo study showing that blockade of the TRPV4-
cytochrome P450 epoxygenase axis only inhibits flow-induced 
vasodilatation in the presence of nitric oxide synthase (NOS) and 
prostacyclin (PGI2) antagonists (Loot et al., 2008). In other words, 
blockade of one endothelium-dependent vasodilatory pathway 
can lead to an acute increase in activity of a compensatory path-
way. Elevated activity in an alternative (and perhaps more potent) 
vasodilatory pathway following loss of TRPV4 activity may also 
explain the subsequent night-time decreases in blood pressure 
following HC-067047 administration, which were not evident in 
vehicle-treated mice (as well as the trend towards hypotension in 
TRPV4 KO mice). A compensatory increase in, for example, NOS 
activity and PGI2 production could also account for the night-time 
decreases in heart rate following TRPV4 antagonism, since both 
are known to produce negative chronotropy (Chiba & Malik, 1980; 
Feron et al., 1998). Further experiments are necessary to determine 
whether the activity of other vasorelaxant pathways is altered in 
TRPV4 knockout animals.
Contrary to expectations, neither TRPV4 gene deletion nor phar-
macological antagonism attenuated LPS-induced haemodynamic 
dysfunction. In fact, both HC-067047-treated and TRPV4 KO mice 
exhibited a trend towards exaggerated hypotension that was most 
evident in measurements of systolic pressure and pulse pressure. 
The exaggerated systolic hypotension and greater decrease in pulse 
pressure observed in both antagonist-treated and KO mice may be 
indicative of reduced cardiac output and left ventricular dysfunction, 
though these parameters were not measured in this study. Reduced 
water intake in these animals prior to the induction of sepsis may 
have contributed to hypovolaemia, decreasing cardiac output. Alter-
natively, it is possible that elevated vascular NO production (in 
response to loss of other TRPV4-dependent vasodilator mechanisms) 
could have increased aortic compliance in these animals, leading to 
greater systolic hypotension and a narrower pulse pressure.
Overall, the haemodynamic consequences of endotoxaemia 
appeared to be worse in mice lacking TRPV4: hypotension was 
slightly exaggerated, and the baroreceptor reflex (compensatory 
tachycardia in response to a fall in blood pressure) was almost 
entirely absent in TRPV4 KO mice. Given that NO is thought to 
antagonise the positive chronotropic effects of increased sympa-
thetic drive (Feron et al., 1998), it is possible that excessive NO 
production in TRPV4 KO mice could account for the bradycardia 
following LPS administration.
Low mesenteric flow is known to correlate strongly with multiple 
organ failure and mortality, both in animal models (Baykal et al., 
2000) and in human patients (Takala, 1996). Clinically, gut ischae-
mia is known as the ‘motor of multiple organ failure’ (Carrico et al., 
1986), probably because impaired mesenteric blood flow is associ-
ated with intestinal hyperpermeability. This breakdown in barrier 
function facilitates the leakage of endotoxins and microorganisms 
into the lymphatic and cardiovascular circulation, which can exac-
erbate the inflammatory response (Sautner et al., 1998). Further-
more, gastric perfusion is known to correlate well with sublingual 
perfusion (Marik, 2001) – a robust indicator of outcome in patients 
(De Backer et al., 2010). Despite numerous reports of an important 
role for TRPV4 in mediating agonist- and flow-induced vasoactive 
responses in small resistance vessels (Adapala et al., 2011; Earley 
et al., 2009; Köhler et al., 2006; Ma et al., 2013; Mendoza et al., 
2010; Sonkusare et al., 2012; Zhang et al., 2009), we did not observe 
any marked changes in mesenteric blood flow in antagonist-treated 
or TRPV4 KO mice. There was, however, a trend towards improved 
flow in 1st and 2nd order vessels in endotoxaemic HC-067047-treated 
mice. Of note, perhaps, is the observation that antagonist-treated 
mice exhibited a trend towards exaggerated hypotension following 
LPS administration, but marginally better mesenteric perfusion; 
these results are consistent with the notion that stabilisation of arte-
rial pressure during sepsis may occur at the expense of microcircu-
latory flow (Sand et al., 2015).
The exact half-life of HC-067047 has not been reported, though 
plasma levels are known to exceed the IC50 for some hours after i.p. 
administration (Everaerts et al., 2010), so we also investigated the 
effect of TRPV4 antagonism on mesenteric blood flow at an earlier 
time-point. At 6 h post-LPS, there was a trend towards lower blood 
flow in antagonist-treated mice, consistent with a vasodilatory role 
for TRPV4 in the mesenteric vasculature, though this was not sta-
tistically significant.
While TRPV4 is known to dilate small resistance vessels (such that 
its blockade may be expected to decrease mesenteric blood flow) 
its activation has also been associated with increased endothelial 
permeability and oedema formation, which would impair perfusion 
(Willette et al., 2008). These divergent effects on microvascular 
blood flow may account for the reverse in trends between 6 h and 
24 h treatment with LPS. Nonetheless, our data do not support a 
prominent role for TRPV4 in regulating mesenteric blood flow 
in this model, either under basal or endotoxaemic conditions. It 
is likely that activity in compensatory pathways is increased both 
acutely and chronically to compensate for its loss.
In contrast to numerous studies demonstrating TRPV4-mediated 
dilatation of mesenteric arteries (Adapala et al., 2011; Earley et al., 
2009; Köhler et al., 2006; Ma et al., 2013; Mendoza et al., 2010; 
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Sonkusare et al., 2012; Zhang et al., 2009) topical application of 
GSK1016790A did not induce any marked changes in blood flow in 
naïve mice. Despite the relatively high concentration used (1 µM), 
it is possible that owing to the aerosolised delivery method (which 
may be prone to evaporation) insufficient concentrations of the ago-
nist contacted vascular receptors. While TRPV4 is expressed in vas-
cular smooth muscle (Earley et al., 2005), the compound may not 
have reached the luminal side of the vessel to induce endothelium- 
dependent vasodilatation. Additional experiments using higher 
concentrations or a different delivery method are required to elu-
cidate this further. The observation that GSK1016790A caused an 
increase in blood flow in LPS-treated mice may indicate inflam-
matory TRPV4 sensitisation, with small amounts of luminal 
GSK1016790A now able to induce vasodilatation, in line with our 
overall hypothesis.
Interestingly, naive TRPV4 KO mice exhibited signs of pathology. 
Blood pH was significantly lower in these animals compared with 
WT counterparts; base excess was correspondingly reduced, and 
partial pressure of CO2 elevated, indicative of respiratory acido-
sis. These data are consistent with a potential acid-sensing role for 
TRPV4 reported previously (Suzuki et al., 2003). The observation 
that blood pH was also slightly reduced in naive HC-067047-treated 
mice relative to vehicle-treated controls, suggests that TRPV4 may 
be involved in maintaining acid-base homeostasis, though the 
mechanism by which this occurs is unclear.
Following the induction of endotoxaemia, TRPV4 KO mice exhib-
ited a more dramatic increase in plasma urea concentration than WT 
mice, consistent with a role for TRPV4 in regulating renal function 
(Liedtke & Friedman, 2003). Although not measured in this study, it 
is possible that loss of TRPV4 activity may result in impaired renal 
circulation. TRPV4 KO mice also exhibited the lowest blood pH of 
all groups during sepsis, but this was not significantly different from 
the mildly acidotic basal pH in these animals. Both antagonist- and 
vehicle-treated WT mice, in contrast, exhibited a significant decline 
in pH between basal and septic conditions, though the magnitude of 
the decrease was less pronounced in HC-067047-treated animals. 
This suggests that blockade of TRPV4 activity may attenuate the 
development of metabolic acidosis. Consistent with this notion, 
base excess was slightly lower and bicarbonate levels slightly 
higher in both antagonist-treated and TRPV4 KO mice, relative to 
vehicle-treated controls.
Both vehicle- and antagonist-treated WT animals became severely 
hyperchloraemic over the course of sepsis. Fluid loss, and perhaps the 
administration of saline resuscitation at the time of sepsis, could have 
contributed to this finding. Hyperchloraemic metabolic acidosis (in 
which serum Cl- levels are elevated, bicarbonate reduced and blood 
pH is low) is also indicative of kidney dysfunction (Walker, 1990). 
Surprisingly, given the elevated plasma urea levels, TRPV4 KO mice 
did not exhibit LPS-induced hyperchloraemia or hypernatraemia.
Following reports linking excessive TRPV4 activation to endothe-
lial failure and oedema formation (Alvarez et al., 2006; Willette et al., 
2008) we aimed to establish the role of TRPV4 in oedema formation 
during endotoxaemia – a condition characterised by increased endothe-
lial permeability (Bridges & Dukes, 2005). No marked changes in the 
ratio of tissue wet-to-dry weight were observed in WT mice follow-
ing 24 h treatment with LPS; only the lung and the kidney exhibited 
trends towards increased plasma extravasation, and values were not 
different between vehicle- and antagonist-treated mice. Although 
these data indicate that oedema is not present at this time-point in 
endotoxaemia pathogenesis, it is possible that the method used is 
insufficiently sensitive to detect small changes in plasma extrava-
sation and interstitial fluid volume. We did observe evidence of 
oedema formation in the kidneys of LPS-treated TRPV4 KO mice 
(there were also trends towards increased wet-to-dry weight ratios 
in the livers and spleens of these animals). This was surprising given 
that these mice did not exhibit an altered ionic balance, and fur-
thermore, because activation of TRPV4 has been associated with 
increased vascular permeability (Alvarez et al., 2006; Willette et al., 
2008). Nonetheless, it appears that deletion of the TRPV4 gene is 
associated with slightly exaggerated oedema formation in the kid-
ney, liver and spleen following LPS administration, though it is not 
clear what mechanism may be involved.
The dose of HC-067047 used in this study (10 mg/kg) was chosen 
based on the only two previous reports of its administration in vivo 
(Everaerts et al., 2010; Materazzi et al., 2012). While the effects of 
systemic TRPV4 antagonism were not dramatic, use of higher con-
centrations was not possible: intraperitoneal injection of 100 mg/kg 
HC-067047 has been shown to cause obvious adverse effects, 
including hunching and piloerection (Everaerts et al., 2010), and 
higher concentrations of DMSO could potentially be toxic. Repeated 
dosing may represent a more viable option for blood flow record-
ing or biochemical analysis, though repeated manual handling and 
intraperitoneal injections would certainly preclude meaningful 
haemodynamic recording. Supplementation of drinking water with 
orally available TRPV4 antagonists (Thorneloe et al., 2012) would 
be required to further elucidate the effects of TRPV4 blockade on 
cardiovascular function in endotoxaemia or sepsis.
Nonetheless, plasma levels of the compound have been shown 
to remain above the IC50 for more than 2 h after intraperitoneal 
administration of 10 mg/kg HC-067047 (Everaerts et al., 2010), 
suggesting that any prominent role for TRPV4 in sepsis-associated 
cardiovascular dysfunction would at least have been evident in the 
early phase of sepsis. The fact that no major changes in haemody-
namics, mesenteric blood flow, blood biochemistry or tissue oedema 
were observed at 6 h post-LPS, suggests either that TRPV4 does not 
play a major role in cardiovascular regulation during endotoxaemia, 
or that other pathways can be upregulated acutely to compensate for 
its loss. However, further studies in which research conditions are 
optimised may yet uncover evidence of a vasoregulatory role for 
TRPV4 in sepsis.
Overall, our data do not support a major role for TRPV4 in sepsis-
associated cardiovascular dysfunction. It is possible that upregula-
tion of alternative vasodilatory pathways may compensate for its 
loss both acutely and chronically, and that changes would only be 
evident on blockade of, for example, NO- and PGI2-dependent path-
ways. Alternatively, since plasma osmolality is known to increase in 
sepsis (Jochberger et al., 2009), and hypertonicity inhibits TRPV4 
activity (Strotmann et al., 2000), it is possible that under septic 
conditions, TRPV4 activity is inhibited such that gene deletion 
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or pharmacological antagonism will produce no further effect. 
Regardless of underlying mechanisms, based on data obtained in 
this study, TRPV4 does not appear to be a viable target in the treat-
ment of sepsis-associated cardiovascular dysfunction.
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Sand examined the hypothesis that loss of TRPV4 function prevents cardiovascular dysfunction inet al. 
sepsis. Using TRPV4-knockout mice and animals treated with TRPV4 inhibitor (HC-067047), the authors
did not find a protective role of TRPV4 deletion/blockade in the model of LPS-induced endotoxaemia.
Although the results are not supportive of the original hypothesis, the study is well-designed and provides
further insight into the role of TRPV4 in the regulation of cardiovascular function.in vivo 
Consistent with previous reports, TRPV4 KO animals (a different colony generated by Liedtke &
Friedman) exhibited lower basal arterial pressure than WT controls during both daytime and night-time
periods while acute administration of TRPV4 antagonist HC-067047 did not significantly alter blood
pressure as compared to vehicle. The minor impact of TRPV4 activity on the regulation of blood pressure
is in contrast to the important role of this channel in vasodilatory response to physical and chemical stimuli
in conduit and resistance arteries. The authors proposed that this discrepancy could be due to the
activation of compensatory pathways in the absence of TRPV4 function. It also remains to be explored
whether TRPV4 function in the vascular tissue could be counteracted by its activity in other tissues such
as those involving in baroreceptor reflex or in long-term sodium/water balance by using tissue-specific
KO.
The endotoxaemic mice used in this study showed only small decrease in blood pressure over baseline,
e.g. an average reduction in MAP of 7.6 mmHg during daytime and 12.9 mmHg at night-time in WT. The
animals also exhibited reduced mesenteric blood flow and lower core body temperature. Together, these
signs seem to indicate a hypodynamic state of sepsis, and the obtained results might underestimate or
overlook hemodynamic effects of TRPV4 activation occurred during an early hyperdynamic stage of
sepsis. This potential limitation could be discussed in the manuscript.
It was also noted that endotoxaemic animals have very low ambulatory activity throughout 24-h period
after LPS and a marked reduction in blood glucose (by as much as 10-fold over baseline). Are these
alterations also found in other similar septic murine models? A reduced ambulatory activity at night-time
could contribute to observed greater reduction in blood pressure during this period after LPS challenge.
Other points
Table 1, column 1. It seems that the comparison should be “BL2-BL1”, “LPS-BL1”, and “LPS-BL2”.
 
Figures 4 and 8, mesenteric blood flow. A large variation in AUC values is noted between the two
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2.  Figures 4 and 8, mesenteric blood flow. A large variation in AUC values is noted between the two
figures.
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Sand examinesd the hypothesis that activity of the Ca2 -permeable the transient receptor potentialet al. 
(TRP) channel TRPV4 contributes to vascular dysfunction in an animal model of sepsis. The study utilized
selective pharmacology and TRPV4 knockout animals to determine if loss of TRPV4 expression would be
protective against sepsis induced by injection of lipopolysaccharide (LPS). Contrary to expectations, loss
or blockade of TRPV4 had very little effect on LPS-induced hypotension. Similarly, reduction in
mesenteric blood flow following LPS administration did not differ between treatment groups. LPS (24
hours) did not induce significant edema formation in control mice, but did cause edema in the kidneys of
TRPV4 knockout mice. Edema was present in some tissues at an earlier (6 hours) time point but this
response was not affected by TRPV4 block. Administration of the TRPV4 agonist GSK1016790A caused
an increase in mesenteric blood flow in 2  and 3  order mesenteric arteries in LPS but not control
animals.
 
This study is clearly written and the work was well designed and properly executed. The guiding
hypothesis - block of TRPV4 channels would diminish vascular effects of sepsis - was based on an
important study that showed circulatory collapses following systemic administration of a TRPV4 activating
drug. This idea is entirely logical and of tremendous interest. Indeed, TRPV4 block appears to improve
pulmonary edema associated with heart failure in rodents ( ). However, the currentThorneloe 2012et al., 
findings do not indicate that block of TRPV4 is beneficial during sepsis. These disparate observations
may reflect important differences between the pulmonary and systemic endothelium. 
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